Structure Therapeutics Stock Soars Over 200% as One Fund Adds to a $242 Million Position

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and ...

Structure Therapeutics: The Dark Horse Has Taken The Lead - But Is It Enough?

Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...
FierceBiotech

In Structure licensing deal, Roche commits $100M to shore up GLP-1 position

In a strategic move that could protect its obesity pipeline from future patent litigation, Roche is paying $100 million to secure a license from Structure Therapeutics. The agreement grants Roche and ...